ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics

Sanofi entered a worldwide strategic collaboration and licensing agreement with ScionxBio to develop extended-exposure versions of certain Sanofi mRNA candidates using ScionxBio's AI-driven TERA platform. ScionxBio, a private preclinical biotech operating as a brand of Eleven Therapeutics, will lead optimization through in vivo validation; Sanofi assumes IND-enabling studies, clinical development, manufacturing, and worldwide commercialization.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.